Bio-Techne Corp (NASDAQ:TECH) released its earnings results on Tuesday. The biotechnology company reported $1.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.10, Bloomberg Earnings reports. Bio-Techne Corp had a return on equity of 13.80% and a net margin of 12.86%. The business had revenue of $156.60 million for the quarter, compared to the consensus estimate of $150.25 million. During the same period in the previous year, the company posted $0.92 earnings per share. The company’s revenue for the quarter was up 16.2% compared to the same quarter last year.

Bio-Techne Corp (NASDAQ TECH) traded down 1.14% on Tuesday, hitting $114.90. The stock had a trading volume of 229,289 shares. The firm has a market cap of $4.29 billion, a PE ratio of 61.81 and a beta of 0.79. Bio-Techne Corp has a 52-week low of $95.68 and a 52-week high of $121.94. The company has a 50-day moving average price of $115.98 and a 200 day moving average price of $108.12.

TECH has been the topic of several analyst reports. Deutsche Bank AG reissued a “buy” rating and issued a $122.00 target price (up from $115.00) on shares of Bio-Techne Corp in a report on Wednesday, May 3rd. BidaskClub raised Bio-Techne Corp from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Zacks Investment Research raised Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a report on Thursday, July 6th. TheStreet raised Bio-Techne Corp from a “c+” rating to a “b” rating in a report on Tuesday, May 2nd. Finally, Wells Fargo & Company initiated coverage on Bio-Techne Corp in a report on Thursday, July 13th. They issued a “market perform” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Bio-Techne Corp has a consensus rating of “Buy” and a consensus price target of $123.20.

COPYRIGHT VIOLATION WARNING: “Bio-Techne Corp (NASDAQ:TECH) Issues Quarterly Earnings Results” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at

In other Bio-Techne Corp news, Director Karen A. Holbrook sold 5,000 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $111.15, for a total transaction of $555,750.00. Following the sale, the director now owns 6,973 shares of the company’s stock, valued at approximately $775,048.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 10,300 shares of company stock worth $1,146,707 in the last ninety days. Insiders own 2.70% of the company’s stock.

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Earnings History for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with's FREE daily email newsletter.